Acceptability of digital health technologies in early Parkinson's disease: lessons from WATCH-PD

被引:0
|
作者
Kangarloo, T. [1 ]
Latzman, R. D. [1 ]
Adams, J. L. [2 ,3 ]
Dorsey, R. [2 ,3 ]
Kostrzebski, M. [2 ,3 ]
Severson, J. [4 ]
Anderson, D. [4 ]
Horak, F. [5 ]
Stephenson, D. [6 ]
Cosman, J. [7 ]
机构
[1] Takeda Pharmaceut, Cambridge, MA 02139 USA
[2] Univ Rochester, Ctr HlthTechnol, Rochester, NY USA
[3] Univ Rochester, Dept Neurol, Rochester, NY USA
[4] Clin Ink, Horsham, PA USA
[5] Oregon Hlth & Sci Univ, Dept Neurol, Balance Disorders Lab, Portland, OR USA
[6] Crit Path Inst, Tucson, AZ USA
[7] Abbvie, N Chicago, IL USA
来源
关键词
digital tool; patient feedback; Parkinson; wearability; wearable sensors; OLDER-ADULTS; PROGRESSION; PEOPLE;
D O I
10.3389/fdgth.2024.1435693
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction Digital health technologies (DHTs) have the potential to alleviate challenges experienced in clinical trials through more objective, naturalistic, and frequent assessments of functioning. However, implementation of DHTs come with their own challenges, including acceptability and ease of use for study participants. In addition to acceptability, it is also important to understand device proficiency in the general population and within patient populations who may be asked to use DHTs for extended periods of time. We thus aimed to provide an overview of participant feedback on acceptability of DHTs, including body-worn sensors used in the clinic and a mobile application used at-home, used throughout the duration of the Wearable Assessments in the Clinic and at Home in Parkinson's Disease (WATCH-PD) study, an observational, longitudinal study looking at disease progression in early Parkinson's Disease (PD).Methods 82 participants with PD and 50 control participants were enrolled at 17 sites throughout the United States and followed for 12 months. We assessed participants' general device proficiency at baseline, using the Mobile Device Proficiency Questionnaire (MDPQ). The mean MDPQ score at Baseline did not significantly differ between PD patients and healthy controls (20.6 [2.91] vs 21.5 [2.94], p = .10).Results Questionnaire results demonstrated that participants had generally positive views on the comfort and use of the digital technologies throughout the duration of the study, regardless of group.Discussion This is the first study to evaluate patient feedback and impressions of using technology in a longitudinal observational study in early Parkinson's Disease. Results demonstrate device proficiency and acceptability of various DHTs in people with Parkinson's does not differ from that of neurologically healthy older adults, and, overall, participants had a favorable view of the DHTs deployed in the WATCH-PD study.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Cognitive effects of safinamide in early Parkinson's disease (PD) patients
    Sharma, T.
    Anand, R.
    Stocchi, F.
    Borgohain, R.
    Rossetti, S.
    MOVEMENT DISORDERS, 2007, 22 : S236 - S237
  • [42] AccessParkinson's disease (PD) Registry Update: Accelerating Parkinson's disease (PD) Research Through Integrated Digital Solutions
    Chang, Y. -H.
    Perinan, M.
    Noyce, A.
    MOVEMENT DISORDERS, 2024, 39 : S316 - S316
  • [43] Pharmacotherapy in the management of early Parkinson's disease: cost-effectiveness and patient acceptability
    Cubo, Esther
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2010, 2 : 127 - 134
  • [44] Defective Autophagy in Parkinson's Disease: Lessons from Genetics
    Zhang, H.
    Duan, C.
    Yang, H.
    MOLECULAR NEUROBIOLOGY, 2015, 51 (01) : 89 - 104
  • [45] Defective Autophagy in Parkinson’s Disease: Lessons from Genetics
    H. Zhang
    C. Duan
    H. Yang
    Molecular Neurobiology, 2015, 51 : 89 - 104
  • [46] Dopamine and the biology of creativity lessons from Parkinson's disease
    Lhommee, Eugenie
    Batir, Alina
    Quesada, Jean-Louis
    Ardouin, Claire
    Fraix, Valerie
    Seigneuret, Eric
    Chabardes, Stephan
    Benabid, Alim-Louis
    Pollak, Pierre
    Krack, Paul
    FRONTIERS IN NEUROLOGY, 2014, 5
  • [47] Modeling Parkinson's Disease: Lessons From the Rotenone Model
    Greenamyre, J. T.
    Cannon, J.
    Drolet, R.
    Hoffman, E.
    Horowitz, M.
    Mastroberardino, P. -G.
    CELL TRANSPLANTATION, 2010, 19 (03) : 341 - 341
  • [48] Enabling efficient use of digital health technologies to support Parkinson's disease drug development through precompetitive collaboration
    Cedarbaum, J.
    Taylor, K.
    Hill, D.
    Alexander, R.
    Luo, Y.
    Rubens, R.
    Zach, N.
    Cosman, J.
    Dowling, A.
    Fisher, K.
    Oliva, L.
    Hitchcock, J.
    Lawton, M.
    Conrado, D.
    Romero, K.
    Minchik, M.
    Meulien, D.
    Yang, B.
    Forman, M.
    Bataille, L.
    Dexter, D.
    Gallagher, J.
    Braxenthaler, M.
    Lindemann, M.
    Boroojerdi, B.
    Stebbins, G.
    Bloem, B.
    Hu, M.
    Dorsey, E.
    Stephenson, D.
    MOVEMENT DISORDERS, 2019, 34 : S33 - S34
  • [49] Hyposmia and apathy in early, de novo Parkinson's disease: Lessons from structural brain connectivity
    Martinez-Nunez, Alfonso E.
    Soltanian-Zadeh, Hamid
    Latack, Katie
    Ghazi, Nayereh
    Mahajan, Abhimanyu
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 452
  • [50] From trials to clinical practice: Lessons from a specialized allied health implementation program for Parkinson's disease
    Darweesh, S.
    Eimers, M.
    van Galen, M.
    Munneke, M.
    Bloem, B.
    MOVEMENT DISORDERS, 2020, 35 : S1 - S3